Not available
Quote | Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH)
Last: | $2.20 |
---|---|
Change Percent: | -3.51% |
Open: | $2.24 |
Close: | $2.20 |
High: | $2.27 |
Low: | $2.18 |
Volume: | 279,969 |
Last Trade Date Time: | 07/28/2020 04:56:12 pm |
News | Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH)
2020 represented a year full of turmoil and despair for some and opportunity for others. There were 154 deals worth over $605 billion announced in 2020. The most interesting aspect of the year was how wide the spreads were in March 2020. For further details see: U.S. Mer...
Merger activity increased last week with four new deals announced and seven deals closing. Over the past month, we have seen early signs of a pickup in new deals and two large deals announced in the energy and healthcare sectors. The acquisition of Noble Energy by Chevron was a significant d...
Message Board Posts | Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH)
Subject | By | Source | When |
---|---|---|---|
* * * $TTPH Chart Analysis * * * | swingingRichard | investorshub | 07/04/2020 7:32:01 AM |
whytestocks: $TTPH News Article - La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceutic | whytestocks | investorshangout | 06/24/2020 12:20:50 PM |
$TTPH News: Written Communication Relating to an Issuer | TheFinalCD | investorshub | 06/22/2020 1:10:14 PM |
Looking good @ 3.15. Imho. | ROCKY LEDGE | investorshub | 06/05/2020 12:21:08 PM |
the algo's just wont let it rebreak 3.25 | TheFinalCD | investorshub | 06/05/2020 12:13:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Tetraphase Pharmaceuticals Inc. Company Name:
TTPH Stock Symbol:
NASDAQ Market:
Tetraphase Pharmaceuticals Inc. Website:
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disease...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Ca...
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an uns...